Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths
Key Points: 1. Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. ...
Key Points: 1. Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. ...
1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8 weeks after treatment compared to placebo. ...
1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8 weeks after treatment compared to placebo. ...
1. Whole-genome sequencing for myeloid cancers, compared to standard cytogenic analysis, was able to more effectively risk-stratify cytogenic cases. 2. ...
Originally published by Harvard Health. What Is It? Myelodysplastic syndromes (MDS) are diseases in which the bone marrow does not make ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.